Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri Withdrawal Prompts Biogen Idec To Suspend Financial Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Company plans to issue revised guidance in May after warning investors not to rely on previous financial forecasts. Announcement coincides with news that a third diagnosis of PML was discovered in a clinical trial for Tysabri.
Advertisement

Related Content

Tysabri Could Return To Market As “Niche” Drug, Analyst Says
Tysabri Could Return To Market As “Niche” Drug, Analyst Says
Tysabri Strength Of Effect Led To Accelerated Approval, FDA Review Shows
Tysabri Strength Of Effect Led To Accelerated Approval, FDA Review Shows
Copaxone Reaches MS Market Share High Following Tysabri Withdrawal
SEC Opens Tysabri Investigation
Rebif Gains New Multiple Sclerosis Rx Share Following Tysabri Withdrawal
Biogen Idec Not A One Product Company, Exec Says
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan

Topics

Advertisement
UsernamePublicRestriction

Register

PS061946

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel